The Australian medicines regulatory authority ‘The Therapeutic Goods Administration’ (TGA) has requested information from Pfizer over claims from a whistle-blower that the company falsified data and failed to follow up adverse reactions quickly.
The whistle-blower Brook Jackson who was a former employee of Ventavia Research Group that was involved in the phase-three trials for the Covid vaccine in 2020 reported to the British Medical Journal (BMJ) that the company “Falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events”
Brook Jackson had been trying to get the information out for a while now. She tried internally multiple times before she emailed a complaint to the US Food and Drug Administration on September 25, 2020. Ventavia sacked Ms Jackson the same day for coming clean on the disturbing activities taking place during the trial.
Ms Jackson has provided many internal company emails, documents, photos and even audio recordings.
When Pfizer applied for FDA approval on December 10th, they failed to disclose the issues with the Phase 3 trials in briefing documents submitted to the FDA advisory committee. The FDA failed to investigate the complaint from Ms Jackson and subsequently issued its emergency use authorisation for the vaccine.
The BMJ also spoke to two additional employees as part of their investigation and found that problems were continuing after Ms Jackson departure. It should be noted that Pfizer has still hired Ventavia to work on additional vaccine clinical trials, including trials on the vaccines use in children, pregnant woman, and ongoing booster doses.